Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn's disease

BMC Gastroenterology

Volumn 17, Issue 1, 2017, Pages

  Lahat, Adi ^a,b   Kopylov, Uri ^a,b   Neuman, Sandra ^a,b   Levhar, Nina ^a,b   Yablecovitch, Doron ^a,b   Avidan, Benjamin ^a,b   Weiss, Batia ^b,c   Ben Horin, Shomron ^a,b   Eliakim, Rami ^a,b   Dotan, Iris ^d   Chowers, Yehuda ^e   Amitai, Marianne M ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Edmond and Lily Safra Children's Hospital   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e Rambam Health Campus ^*  (Israel)

Author keywords

Crohn's disease; Eradication; Helicobacter pylori; Prevalence; Video capsule endoscopy

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AMOXICILLIN; C REACTIVE PROTEIN; CALGRANULIN; CLARITHROMYCIN; ESOMEPRAZOLE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFECTIVE AGENT;

ADULT; ANTIGEN DETECTION; ARTICLE; BACTERIAL CLEARANCE; CAPSULE ENDOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; FECES ANALYSIS; FEMALE; GASTROENTERITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAGNETIC RESONANCE ENTEROGRAPHY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PROSPECTIVE STUDY; REMISSION; TREATMENT PLANNING; CHEMISTRY; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE ERADICATION; FECES; HELICOBACTER INFECTIONS; MICROBIOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; CAPSULE ENDOSCOPY; CROHN DISEASE; DISEASE ERADICATION; FECES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 85013018473     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-017-0588-7     Document Type: Article

References (31)

1. World Gastroenterology Organisation Global Guidelines Helicobacter pylori in developing countries, August 2010. Available at: www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2010.pdf. last Accessed 10 Nov 2015
2. Sonnenberg A. Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther. 2013;38:329-42.
3. Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20(18):5191-204.
4. Love JR, Irvine EJ, Fedorak RN. Quality of life in IBD. J Clinical Gastroenterol. 1992;14:15-9.
5. Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488-96.
6. Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004;19:529-35.
7. Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol. 2001;13:567-72.
8. Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther. 2006;23:377-85.
9. Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012;18:3790-9.
10. Sonnenberg A, Genta RM. Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:469-76.
11. Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, et al. Helicobacter pylori and Crohn's disease: a retrospective single-center study from China. World J Gastroenterol. 2013;19:4576-81.
12. Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:439-43.
13. El-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut. 1994;35:1385-8.
14. D'Incà R, Sturniolo G, Cassaro M, di Pace C, Longo G, Callegari I, et al. Prevalence of upper gastrointestinal lesions and Helicobacter pylori infection in Crohn's disease. Dig Dis Sci. 1998;43:988-92.
15. Parente F, Molteni P, Bollani S, Maconi G, Vago L, Duca PG, et al. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching. Scand J Gastroenterol. 1997;32:1140-6.
16. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol. 2003;36:22-5.
17. Pellicano R, Bresso F, Demarchi B, Bertolusso L, Sapone N, Rizzetto M, et al. Prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease: pilot study. Rev Esp Enferm Dig. 2010;102:675-66. author reply 676.
18. Triantafillidis JK, Gikas A, Apostolidiss N, Merikas E, Mallass E, Peros G. The low prevalence of helicobacter infection in patients with inflammatory bowel disease could be attributed to previous antibiotic treatment. Am J Gastroenterol. 2003;98:1213-4.
19. Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut. 2015 Oct 27. pii: gutjnl-2015-310545. doi: 10.1136/gutjnl-2015-310545. [Epub ahead of print]
20. Roka K, Roma E, Stefanaki K, Panayotou I, Kopsidas G, Chouliaras G. The value of focally enhanced gastritis in the diagnosis of pediatric inflammatory bowel diseases. J Crohns Colitis. 2013;7:797-802.
21. Sonnenberg A, Melton SD, Genta RM. Frequent occurrence of gastritis and duodenitis in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:39-44.
22. Halme L, Kärkkäinen P, Rautelin H, Kosunen TU, Sipponen P. High frequency of helicobacter negative gastritis in patients with Crohn's disease. Gut. 1996;38:379-83.
23. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
24. Arnold IC, Hitzler I, Muller A. The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol. 2012;2:10.
25. Shrot S, Konen E, Hertz M, Amitai MM. Magnetic resonance enterography: 4 years experience in a tertiary medical center. Isr Med Assoc J. 2011;13(3):172-7.
26. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018.
27. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016 May-Jun;23(3):e880-93.
28. Samra Z, Shmuely H, Niv Y, Dinari G, Passaro DJ, Geler A, et al. Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother. 2002;49:1023-6.
29. Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2016;28:676-83.
30. Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial.Gut Liver. 2016 Apr 28. doi: 10.5009/gnl15470. [Epub ahead of print]
31. Lai KC, Hui WM, Wong BC, Hu WH, Lam SK. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther. 2000;14:1071-6.